Literature DB >> 22795320

Treatment of paediatric epilepsy in Germany: antiepileptic drug utilisation in children and adolescents with a focus on new antiepileptic drugs.

Michael Dörks1, Ingo Langner, Antje Timmer, Edeltraut Garbe.   

Abstract

BACKGROUND: Treatment of paediatric epilepsy has advanced with the development of new antiepileptic drugs (AEDs). There are few data for Germany to which extent new AEDs are used in the treatment of childhood epilepsy. AIMS: To characterise utilisation of antiepileptics in children and adolescents with a specific emphasis on new AEDs.
METHODS: Data were obtained from the German Pharmacoepidemiological Research Database for the period 2004-2006. Descriptive analyses were performed to assess prevalence and incidence of AED use stratified by age and sex. Mono- and combination therapy were considered as well as diagnoses and physician speciality.
RESULTS: We identified 13,197 children with AED use who received a total of 226,856 AED prescriptions. The majority of children treated with an AED were diagnosed with epilepsy (11,872; 89.96%). Of all AED prescriptions, 140,992 (62.15%) were for conventional and 85,864 (37.85%) were for new AEDs. One-year prescribing prevalence ranged between 4.10 and 4.11 per 1000 children. Incidence of AED use was 0.91 (95% CI: 0.87-0.95) per 1000 person-years in 2005 and 0.84 (95% CI: 0.81-0.89) per 1000 person-years in 2006. Monotherapy (9821; 74.42%) was more prevalent than combination therapy. Most AEDs were prescribed by paediatricians (147,150; 64.86%).
CONCLUSIONS: The introduction of the new AEDs had less impact on prescribing of AEDs in children than has been reported for adults. AED prescribing overall was in line with published guidelines.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22795320     DOI: 10.1016/j.eplepsyres.2012.06.008

Source DB:  PubMed          Journal:  Epilepsy Res        ISSN: 0920-1211            Impact factor:   3.045


  8 in total

1.  [Impact of early benefit assessment on patients with epilepsy in Germany: Current healthcare provision and therapeutic needs].

Authors:  A Strzelczyk; H M Hamer
Journal:  Nervenarzt       Date:  2016-04       Impact factor: 1.214

2.  Antiepileptic drug use in Italian children over a decade.

Authors:  Daria Putignano; Antonio Clavenna; Rita Campi; Angela Bortolotti; Ida Fortino; Luca Merlino; Aglaia Vignoli; Maria Paola Canevini; Maurizio Bonati
Journal:  Eur J Clin Pharmacol       Date:  2016-11-26       Impact factor: 2.953

3.  Factors associated with seizure recurrence in epilepsy patients treated with antiepileptic monotherapy: A retrospective observational cohort study using US administrative insurance claims.

Authors:  Natalia Shcherbakova; Karen Rascati; Carolyn Brown; Kenneth Lawson; Suzanne Novak; Kristin M Richards; Linda Yoder
Journal:  CNS Drugs       Date:  2014-11       Impact factor: 5.749

Review 4.  Genetics and Extracellular Vesicles of Pediatrics Sleep Disordered Breathing and Epilepsy.

Authors:  Abdelnaby Khalyfa; David Sanz-Rubio
Journal:  Int J Mol Sci       Date:  2019-11-04       Impact factor: 5.923

5.  Anti-seizure Medication Prescription in Adult Outpatients With Epilepsy in China, 2013-2018.

Authors:  Lingyan Yu; Wenjie Zhu; Xiuping Zhu; Yan Lu; Zhenwei Yu; Haibin Dai
Journal:  Front Neurol       Date:  2021-05-24       Impact factor: 4.003

6.  Predictors of Poor Seizure Control in Children Managed at a Tertiary Care Hospital of Eastern Nepal.

Authors:  Prakash Poudel; Mohit Chitlangia; Rita Pokharel
Journal:  Iran J Child Neurol       Date:  2016

7.  Anti-epileptic drug utilisation in paediatrics: a systematic review.

Authors:  Oluwaseun Egunsola; Imti Choonara; Helen M Sammons
Journal:  BMJ Paediatr Open       Date:  2017-08-11

8.  Trends in Prescribing of Antiseizure Medications in South Korea: Real-World Evidence for Treated Patients With Epilepsy.

Authors:  Kyung Wook Kang; Hyesung Lee; Ju-Young Shin; Hye-Jin Moon; Seo-Young Lee
Journal:  J Clin Neurol       Date:  2022-03       Impact factor: 3.077

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.